Skip to Navigation Skip to Search Skip to Content
Search All Centers

Newly Approved Drug for CLL: Acalabrutinib (Calquence)

View next

Published on November 21, 2019

The FDA has approved a new chronic lymphocytic leukemia drug: acalabrutinib (Calquence). Want to learn more about this newly approved drug? Watch our CLL video with expert Dr. William Wierda from MD Anderson Cancer Center to learn more about the treatment.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

 

What a wonderful time we had! We were excited like fans at a rock concert, but our rock stars were the medical experts.

— Lynn, CLL town meeting attendee

View next